Belite Bio (BLTE) Non Operating Income (2022 - 2026)

Belite Bio's Non Operating Income history runs 5 years deep, the most recent figure standing at $5.7 million for Q1 2026.

• On a quarterly basis, Non Operating Income rose 363.39% year-over-year to $5.7 million in Q1 2026; TTM through Mar 2026 was $5.4 billion, a 57.9% increase from a year earlier, with the FY2025 full-year figure at $6.6 million, up 71.0% from the prior year.
• Non Operating Income declined to $5.7 million in Q1 2026 per BLTE's latest filing, from $2.8 billion in the prior quarter.
• Across five years, Non Operating Income topped out at $2.8 billion in Q4 2025 and bottomed at -$8.0 million in Q1 2023.
• The 5-year median for Non Operating Income is $126.0 million (2022), against an average of $595.5 million.
• Across the five-year window, Non Operating Income plunged 99.98% in 2023 and soared 3929529.63% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$62000.0 in 2022, then surged by 41.94% to -$36000.0 in 2023, then jumped by 3769544.44% to $1.4 billion in 2024, then soared by 102.87% to $2.8 billion in 2025, then plunged by 99.79% to $5.7 million in 2026.
• Per Business Quant, the three latest BLTE Non Operating Income figures stand at $5.7 million (Q1 2026), $2.8 billion (Q4 2025), and $1.3 billion (Q3 2025).